Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ianalumab plus eltrombopag versus placebo plus eltrombopag in adults with primary immune thrombocytopenia
NL-OMON56456Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Oct 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ianalumab and eltrombopag in immune thrombocytopenia (ITP) (3 arms), sponsored by Novartis. Primary endpoint: Time to treatment failure. Started Oct 2023; status: recruiting.
02
Drugs
ianalumabeltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NL-OMON56456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56456.